WAVE Life Sciences Ltd.
WVE
$13.02
-$0.33-2.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -79.41% | 199.11% | -55.82% | -26.82% | 188.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.41% | 199.11% | -55.82% | -26.82% | 188.23% |
| Cost of Revenue | 18.30% | 11.35% | 7.62% | 21.45% | 31.02% |
| Gross Profit | -190.96% | 21.70% | -67.96% | -50.40% | 879.25% |
| SG&A Expenses | 29.51% | 20.24% | 25.83% | 35.49% | 18.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.27% | 13.73% | 12.38% | 25.50% | 27.32% |
| Operating Income | -345.86% | 11.83% | -50.75% | -44.54% | 222.94% |
| Income Before Tax | -281.79% | 12.83% | -53.29% | -48.55% | 279.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -281.79% | 12.83% | -53.29% | -48.55% | 279.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -281.79% | 12.83% | -53.29% | -48.55% | 279.95% |
| EBIT | -345.86% | 11.83% | -50.75% | -44.54% | 222.94% |
| EBITDA | -332.99% | 11.86% | -52.64% | -46.42% | 235.64% |
| EPS Basic | -262.89% | 31.12% | -21.09% | -18.15% | 222.12% |
| Normalized Basic EPS | -262.90% | 31.10% | -21.08% | -18.15% | 222.11% |
| EPS Diluted | -273.73% | 31.12% | -21.09% | -18.15% | 211.13% |
| Normalized Diluted EPS | -273.80% | 31.10% | -21.08% | -18.15% | 214.46% |
| Average Basic Shares Outstanding | 11.64% | 26.53% | 26.60% | 25.73% | 47.31% |
| Average Diluted Shares Outstanding | 4.64% | 26.53% | 26.60% | 25.73% | 57.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |